Epstein-Barr virus BCRF1 gene product (viral interleukin 10) inhibits superoxide anion production by human monocytes

H. Niiro, T. Otsuka, M. Abe, H. Satoh, T. Ogo, T. Nakano, Y. Furukawa, Y. Niho

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Due to its similar biological activities to interleukin 10 (IL-10), Epstein-Barr virus (EBV) BCRF1 gene product (viral IL-10: vIL-10) has recently been recognized as an analogue of authentic IL-10. Preincubation of human monocytes with vIL-10, like human IL-10, induced smaller amounts of interferon-γ (IFN-γ) mRNA in activated human peripheral blood mononuclear cells (PBMNCs) than nonpreincubation, indicating that vIL-10 acts principally on monocytes. Since the activation of monocytes and their generation of oxidative products are regulated by various cytokines, we examined the effects of vIL-10 on superoxide anion (O2-) production by human PBMNCs and monocytes. Not only PBMNCs but also monocytes preincubated with vIL-10 showed a smaller production of O2-. Inhibition was achieved in a dose-dependent fashion and increased gradually after incubation with vIL-10. Additions of IFN-γ, macrophage colony-stimulating factor (M-CSF) or granulocyte- macrophage colony-stimulating factor (GM-CSF), which prime monocyte activation and induce O2- production, were also affected by the reciprocal effect of vIL-10. Thus, vIL-10 production by EBV-infected cells may be involved in the development of EBV-related disorders.

Original languageEnglish
Pages (from-to)209-214
Number of pages6
JournalLymphokine and Cytokine Research
Volume11
Issue number5
Publication statusPublished - Jan 1 1992

    Fingerprint

All Science Journal Classification (ASJC) codes

  • Immunology
  • Hematology

Cite this